AnalyzeDirect Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. November 2004;64(21):7995-8001.
Full Text – Open Access
Publication Date
November 2004
How Analyze was Used
“Image analysis and display was performed with Analyze 4.0 (AnalyzeDirect Inc., Lenexa, KS).”
Keywords
Animals
Antibodies, Monoclonal/therapeutic use
Antigens, Surface
Antineoplastic Agents/therapeutic use
Bone Neoplasms/secondary
Glutamate Carboxypeptidase II/antagonists & inhibitors
Humans
Immunotoxins/therapeutic use
Male
Maytansine/analogs & derivatives/therapeutic use
Mice
Neoplasm Transplantation
Prostatic Neoplasms/therapy
Transplantation, Heterologous
Author Affiliation(s)
Department of Cancer Pharmacology, Millennium Pharmaceuticals, Inc., Cambridge, MA, US. (MDH, SW, PJW)
Department of Imaging Sciences, Millennium Pharmaceuticals, Inc., Cambridge, MA, US. (MDS, SC)
Department of Drug Safety and Disposition, Millennium Pharmaceuticals, Inc., Cambridge, MA, US. (MM)
ID# 2182
Tags: Animals, Antibodies, Antineoplastic Agents/therapeutic use, Bone Neoplasms/secondary, Glutamate Carboxypeptidase II/antagonists & inhibitors, Heterologous Transplantation, Humans, Immunotoxins/therapeutic use, Male, Maytansine/analogs & derivatives/therapeutic use, Mice, Monoclonal/therapeutic use, Neoplasm Transplantation, Prostatic Neoplasms/therapy, Surface Antigens